Last reviewed · How we verify

Cyclophosphamide and azathioprine — Competitive Intelligence Brief

Cyclophosphamide and azathioprine (Cyclophosphamide and azathioprine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive agents / Cytotoxic agents. Area: Immunology / Rheumatology.

phase 3 Immunosuppressive agents / Cytotoxic agents Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Cyclophosphamide and azathioprine (Cyclophosphamide and azathioprine) — Assistance Publique - Hôpitaux de Paris. This combination uses cyclophosphamide as an alkylating agent and azathioprine as a purine antagonist to suppress immune cell proliferation and function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cyclophosphamide and azathioprine TARGET Cyclophosphamide and azathioprine Assistance Publique - Hôpitaux de Paris phase 3 Immunosuppressive agents / Cytotoxic agents

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive agents / Cytotoxic agents class)

  1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cyclophosphamide and azathioprine — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclophosphamide-and-azathioprine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: